November 8, 2024
Abion’s ‘Vabametkib’ NSCLC Phase 1 CSR receives safety confirmation, Phase 2 progressing smoothly
Abion revealed on November 6 that it received the phase 1 Clinical Study Report (CSR)…
October 16, 2024
Abion CEO Shin Young Kee “Vabametkib and Lazertinib combination cohort filling for 3Q”
- Combination strategy unveiled at ASCO: “Safety confirmed, Cohort 2 to launch in H2 2024”…
October 16, 2024
ABION Vice President Choi Jun-young: “AI-enhanced MET CTC test ensures fast and accurate lung cancer screening”
- "Application of liquid biopsy and AI in clinical trials for 'vabametkib + lazertinib' combination…
September 24, 2024
ABION, Inc. to Speak at ACCESS CHINA Partnering Forum
September 23rd, 2024 (Shanghai) — We are glad to announce that Hong Seok Choi, Business Development…
June 28, 2024
Abion signed agreement with Johnson & Johnson on drug supply for combination clinical trial
Abion and Janssen Research and Development, LLC, a Johnson & Johnson company have entered into…
October 16, 2023
With positive phase II interim data in NSCLC, Abion to advance MET-TKI to combo trial
With positive phase II interim data in NSCLC, Abion to advance MET-TKI to combo trial…
